Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Aurobindo Pharma Limited — Q3 FY25
Aurobindo Pharma delivered its highest-ever quarterly revenue of INR 7,979 crore in Q3 FY25, driven by robust US base product sales, strong European growth (+23% YoY), and expansion in growth markets (+39% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aurobindo Pharma delivered its highest-ever quarterly revenue of INR 7,979 crore in Q3 FY25, driven by robust US base product sales, strong European growth (+23% YoY), and expansion in growth markets (+39% YoY). EBITDA margin stood at 20.4%, with gross margins expanding 130 bps YoY to 58.4%. Management reiterated its FY25 EBITDA margin guidance of 21%-22%, expecting a stronger Q4 driven by increased transient sales and operational efficiencies. Key growth drivers include the ramp-up of the China plant (contributing from FY26), commercialization of the Dayton OSD facility, and progress in biosimilars with positive CHMP opinions for Filgrastim and Pegfilgrastim. However, the injectables business (Eugia) continues to face capacity utilization challenges at ~50%, though management expects a return to normal run-rate from Q4. Risk: Potential pricing erosion and market share loss for generic Revlimid post patent expiry in January 2026.
ऑरोबिंदो फार्मा ने वित्त वर्ष 2025 की तीसरी तिमाही में अब तक का सबसे बड़ा कारोबार किया - 7,979 करोड़ रुपये। यह अमेरिका में दवाओं की अच्छी बिक्री, यूरोप में 23% और दूसरे बढ़ते बाजारों में 39% ज्यादा बिक्री से हुआ। कंपनी का मुनाफा मार्जिन (EBITDA) 20.4% रहा, जो पिछले साल से बेहतर है। कंपनी को उम्मीद है कि चौथी तिमाही में यह 21-22% तक पहुंच जाएगा, क्योंकि बिक्री बढ़ेगी और खर्च कम होंगे। नए कारखानों (चीन और अमेरिका में) से अगले साल से फायदा मिलेगा। बायोसिमिलर दवाओं को भी यूरोप में मंजूरी मिल रही है। हालांकि, इंजेक्शन वाले कारोबार (यूजिया) में अभी क्षमता का सिर्फ 50% इस्तेमाल हो रहा है, लेकिन चौथी तिमाही से सुधार की उम्मीद है। खतरा: जनवरी 2026 में जेनेरिक रेवलिमिड के पेटेंट खत्म होने पर कीमतें गिर सकती हैं और बाजार हिस्सेदारी घट सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Generic Revlimid patent expiry impact
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Formulation Revenue
$435M
+3.3% QoQ
Sequential growth driven by volume gains and stable pricing; injectables impacted by transient sales and cut-off issues.
Europe Formulation Revenue
€236M
+23% YoY
Strong growth across key European geographies, supported by robust portfolio and supply chain.
Growth Markets Revenue
INR 873 Cr
+39% YoY
Driven by successful geographical expansion and strong sales momentum in emerging markets.
Eugia Capacity Utilization
50%
-20pp vs normal
Utilization impacted by supply challenges; expected to return to 65-70% from Q4 FY25.
What Changed vs Last Quarter
NEW
China plant to contribute from FY26
The China OSD plant (2B units capacity) commercialized in November 2024, expected to ramp up and contribute to revenues in FY26, initially supplying Europe.
NEW
Dayton OSD plant commercialization in next fiscal
The US-based OSD plant at Dayton is expected to be commercialized in FY26, adding capacity for the US market.
NEW
Biosimilar launches in EU from July 2025
Following positive CHMP opinions, Filgrastim and Pegfilgrastim expected to launch in EU in Q2 FY26, with revenue bookings starting from that quarter.
UPDATED
FY25 EBITDA margin guidance of 21%-22%
Management reaffirmed achieving 21%-22% EBITDA margin for FY25, despite Q3 margin of 20.4%, citing stronger Q4 with increased transient sales and operational efficiencies.
DROPPED
Penicillin G breakeven by Q4 FY25
Expect to achieve breakeven at the penicillin G facility by Q4 FY25, with positive contribution from FY26.
DROPPED
Global Eugia injectable sales ~$600M for FY25
Despite Q1/Q2 slowdown, management expects full-year injectable sales to be around $600M, with a possible 5% variance.
DROPPED
Biosimilar denosumab commercial in Europe by CY2026
Phase III recruitment completed; filing expected in 2025 with commercialization in Europe in 2026.
NEW RISK
Generic Revlimid patent expiry impact
Patent expiry in January 2026 could lead to pricing erosion and market share loss; management acknowledged uncertainty but plans to continue supply post-expiry.
NEW RISK
Eugia injectables capacity ramp-up delays
Capacity utilization at Eugia remains at 50% due to supply challenges; any further delays in returning to normal run-rate could impact US injectable revenue.
NEW RISK
Biosimilar clinical trial delays
Omalizumab and ophthalmic product trials are delayed; ophthalmic recruitment only 50% and expected to complete in H2 2026, pushing back potential launches.
NEW RISK
US tariff risk on pharmaceuticals
Potential US tariffs on pharmaceutical imports could impact margins; management believes existing US manufacturing footprint provides mitigation.
RISK GONE
Sustained high R&D spend
R&D costs jumped ~INR 70 crore in Q2 due to phase III biosimilar trials; management expects elevated spend for at least four more quarters.
RISK GONE
Freight cost volatility from Red Sea disruptions
Higher freight costs (~INR 30 crore impact) due to Red Sea issues; management expects normalization but uncertainty remains.
RISK GONE
Unit 3 injectable supply chain recovery timeline
Injectable sales declined 11% YoY due to voluntary production slowdown at Unit 3; full recovery expected only by Q4, with FDA reinspection likely in FY26 Q3.
RISK GONE
Biosimilar omalizumab recruitment delays
Phase III recruitment for omalizumab is 3-4 months behind schedule, potentially pushing back filing timelines.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24, Q4 FY24
Management reiterated internal target for full-year EBITDA margin, implying H2 margins will be higher than H1.
Mentioned in Q1 FY24, Q2 FY24
On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.
Mentioned in Q1 FY24, Q1 FY25
Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
Mentioned in Q1 FY25, Q2 FY24
Management expects current US pricing scenario to continue; low single-digit price erosion in injectables could pressure margins.
Fast read
Guidance and risk preview
Management reaffirmed achieving 21%-22% EBITDA margin for FY25, despite Q3 margin of 20.4%, citing stronger Q4 with increased transient sales and o...
Patent expiry in January 2026 could lead to pricing erosion and market share loss; management acknowledged uncertainty but plans to continue supply...
View Risks →